Compare VRTS & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VRTS | ARDX |
|---|---|---|
| Founded | 1988 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 790.2M | 724.0M |
| IPO Year | 1995 | 2014 |
| Metric | VRTS | ARDX |
|---|---|---|
| Price | $100.77 | $2.99 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $133.75 | $12.50 |
| AVG Volume (30 Days) | 101.4K | ★ 4.4M |
| Earning Date | 11-09-2026 | 11-03-2026 |
| Dividend Yield | ★ 9.24% | N/A |
| EPS Growth | ★ 18.24 | N/A |
| EPS | ★ 10.96 | N/A |
| Revenue | N/A | ★ $2,607,000.00 |
| Revenue This Year | N/A | $18.39 |
| Revenue Next Year | N/A | $26.08 |
| P/E Ratio | $9.68 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $105.53 | $2.80 |
| 52 Week High | $175.66 | $8.40 |
| Indicator | VRTS | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 31.03 | 43.02 |
| Support Level | N/A | $2.88 |
| Resistance Level | $147.37 | $3.38 |
| Average True Range (ATR) | 6.50 | 0.17 |
| MACD | -2.10 | 0.02 |
| Stochastic Oscillator | 2.59 | 30.33 |
Virtus Investment Partners Inc provides investment management and related services to institutions and individuals. It uses a multi-manager, multi-style approach, offering investment strategies from investment managers, each having its distinct investment style, autonomous investment process, and individual brand, as well as from select unaffiliated managers for certain funds. Through its multi-manager model, the group provides investment managers with distribution, business, and operational support. The Company operates in one business segment, namely as an asset manager providing investment management and related services for individual and institutional clients.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.